Patients with ovarian cancer have a high risk of developing thrombosis. We aimed to investigate pre and post operative biomarkers associated with thrombosis including deep vein thrombosis and pulmonary thromboembolism in patients treated for ovarian cancer. We collected pre and post operative blood samples from 133 patients undergoing surgery for ovarian cancer between December 2021 and August 2022. The measured parameters were white blood cell count, hemoglobin, platelets, monocytes, serum glucose, CA125, D-dimer, fibrinogen, prothrombin time, activated partial thromboplastin time, fibrinogen degradation products, antithrombin III, protein C, protein S, plasminogen, plasminogen activator inhibitor 1, homocysteine, N-terminal pro-brain natriuretic peptide, interleukin 6, thrombopoietin, soluble P-selectin and granulocyte stimulating factor. Body mass index of patients were collected. Differences between patients who developed thrombosis and those without were compared with Wilcoxon rank-sum test and we analyzed the continuous variables using logistic regression. Twenty-one (15.8%) patients developed thrombosis ranging from 6 to 146 days (median 15 days) after surgery. Pre operative values of homocysteine (p = 0.033) and IL-6 (p = 0.043) were significantly increased and post operative aPTT (p = 0.022) was prolonged and plasminogen (p = 0.041) was decreased in patients with thrombosis. It is important to find novel biomarkers for thrombosis to carefully manage patients who are prone to develop thrombosis despite preventive measures were applied.

卵巢癌患者发生血栓的风险很高。我们的目的是研究卵巢癌治疗患者术前和术后与血栓形成相关的生物标志物，包括深静脉血栓形成和肺血栓栓塞。我们收集了2021年12月至2022年8月期间接受卵巢癌手术的133名患者的术前和术后血样。测量参数为白细胞计数、血红蛋白、血小板、单核细胞、血糖、CA125、D-二聚体、纤维蛋白原、凝血酶原时间、活化部分凝血活酶时间、纤维蛋白原降解产物、抗凝血酶 III、蛋白 C、蛋白 S、纤溶酶原、纤溶酶原激活剂抑制剂 1、同型半胱氨酸、N 端脑钠肽前体、白细胞介素 6、血小板生成素、可溶性 P-选择素和粒细胞刺激剂因素。收集患者的体重指数。使用 Wilcoxon 秩和检验比较发生血栓的患者与未发生血栓的患者之间的差异，并使用逻辑回归分析连续变量。21 名 (15.8%) 患者在术后 6 至 146 天（中位 15 天）内出现血栓形成。血栓患者术前同型半胱氨酸 ( p  = 0.033) 和 IL-6 ( p  = 0.043) 值显着升高，术后 aPTT ( p  = 0.022) 延长，纤溶酶原 ( p  = 0.041) 降低。重要的是找到新的血栓形成生物标志物，以仔细管理尽管采取了预防措施但仍容易发生血栓形成的患者。